Pharmazz, a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, has announced a $25 million equity investment from Sun Pharmaceutical Industries Limited, one of the world's leading pharmaceutical companies. This strategic investment brings Sun Pharma's total commitment in Pharmazz to $40 million (including a previous $15 million equity investment)..

Pharmazz是一家致力于开发重症监护和神经病学领域未满足医疗需求的创新疗法的后期生物制药公司，近日宣布获得全球领先的制药公司之一——太阳制药工业有限公司（Sun Pharmaceutical Industries Limited）2500万美元的股权投资。此次战略性投资使太阳制药对Pharmazz的总投资额达到4000万美元（包括此前的1500万美元股权投资）。